key: cord-0872139-qhfgi02d
authors: Wiwanitkit, Viroj
title: Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence
date: 2020-06-22
journal: Int J Surg
DOI: 10.1016/j.ijsu.2020.06.029
sha: c6a66453cfed14a71b8aed1a921017cb40726237
doc_id: 872139
cord_uid: qhfgi02d

nan

Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence Dear Editor, I would like to share ideas on "Convalescent plasma therapy in the treatment of COVID-19: practical considerations: Correspondence." is very interesting [1] . Islam et al. noted that "While we await trial results, we recommend that CPT be considered for patients severely ill with COVID-19 upon hospitalization [1] ." Convalescent plasma therapy is still not scientifically proven for its usefulness and safety. In fact, Islam et al. already mentioned for considerations on possible problem due to pathogen contamination in convalescent plasma [1] . At present, there is still no scientific proof that the presently use plasma preparation technique in all blood banks can successfully remove all pathogens. There are many other classic therapeutic options that might pose lower risk for management of COVID-19 such as the use of classic drug, hydroxychloroquine. Finally, whether the convalescent plasma can act against the novel coronavirus or not still requires further studies. There are some evidences on possible repeated COVID-19 infection in patients recovered from COVID-19 [2 -3] . This can imply that there is a chance that there will be no protective immunity in plasma of patients recovered from a COVID-19 illness.

None Provenance and peer review Not Commissioned, internally reviewed

The following additional information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories, then this should be stated. 

Please cite this article as: Wiwanitkit V, Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence

Convalescent plasma therapy in the treatment of COVID-19: practical considerations: Correspondence

Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19

Re-infection by COVID-19: a real threat for the future management of pandemia? Infect Dis (Lond)

Name of the registry: not applicable 2. Unique Identifying number or registration ID: not applicable 3. Hyperlink to your specific registration

Please enter the name of the registry, the hyperlink to the registration and the unique identifying number of the study. You can register your research at http://www.researchregistry.com to obtain your UIN if you have not already registered your study. This is mandatory for human studies only.

Please specify the contribution of each author to the paper, e.g. study design, data collections, data analysis, writing. Others, who have contributed in other ways should be listed as contributors.Wiwanitkit 100 %

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. Please note that providing a guarantor is compulsory.